Exhibit 99.1

FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G, dated August 26, 2022 (the “Schedule 13G”), with respect to the common Stock, par value $0.0001 per share, of Akili, Inc. is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an exhibit to the Schedule 13G and each such amendment.

Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 26th day of August, 2022.

Dated: August 26, 2022	TEMASEK HOLDINGS (PRIVATE) LIMITED
	By:	/s/ Jason Norman Lee
		Name:	Jason Norman Lee
		Title:	Authorized Signatory

Dated: August 26, 2022	FULLERTON MANAGEMENT PTE LTD
	By:	/s/ Gregory Tan
		Name:	Gregory Tan
		Title:	Director

Dated: August 26, 2022	TEMASEK LIFE SCIENCES PRIVATE LIMITED
	By:	/s/ Lim Siew Lee Sherlyn
		Name:	Lim Siew Lee Sherlyn
		Title:	Director

Dated: August 26, 2022	TLS BETA PTE. LTD.
	By:	/s/ Zahedah Abdul Rashid
		Name:	Zahedah Abdul Rashid
		Title:	Director